Nephrology
Latest news
138 articles · 20 / page
Higher Hospital-Level Utilization of Continuous Kidney Replacement Therapy Associated with Reduced Mortality in Critically Ill Patients
A large-scale multicenter study reveals that hospitals with higher utilization rates of continuous kidney replacement therapy (CKRT) achieve significantly lower 90-day mortality for critically ill AKI patients compared to low-utilization ce
Severe Acute Kidney Injury Survivors in India and Southeast Asia Face Staggering Rates of Long-Term Adverse Events
A large-scale multicenter study reveals that 46.6% of severe AKI survivors in India and Southeast Asia experience major adverse kidney events (MAKE) within two years, with mortality and new-onset chronic kidney disease being the primary dri
Beyond eGFR and UACR: kidneyintelX.dkd Refines Risk Stratification and Monitors Treatment Response in Diabetic Kidney Disease
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
Kidney Replacement Therapy Independently Predicts 90-Day Mortality in Critically Ill Patients with Obesity: A 15-Year Trend Analysis
A 15-year cohort study reveals that obese ICU patients requiring kidney replacement therapy face nearly triple the mortality rate of those who do not, despite a declining trend in overall acute kidney injury incidence within this high-risk
Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP
Optimizing Acid-Base Stability in CVVH: Why Lower Bicarbonate Fluids Outperform Standard Concentrations During Regional Citrate Anticoagulation
This randomized controlled trial demonstrates that a lower bicarbonate replacement fluid (22 mmol/l) provides superior acid-base stability compared to a higher concentration (30 mmol/l) during CVVH with citrate anticoagulation, significantl
Empagliflozin Enhances Cardiovascular Protection in HFrEF Patients with Low Serum Magnesium: Evidence from EMPEROR-Reduced
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know
A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu
Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies
A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.
Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active
Pegcetacoplan Markedly Reduces Proteinuria in C3 Glomerulopathy and Immune‑Complex MPGN: Results from the VALIANT Phase 3 Trial
In the phase 3 VALIANT trial, pegcetacoplan, a C3/C3b inhibitor, produced a large, rapid reduction in proteinuria versus placebo at 26 weeks in patients with C3 glomerulopathy or primary immune‑complex MPGN, with an acceptable short-term sa
Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds
In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Outcomes of Empagliflozin in Heart Failure with Preserved Ejection Fraction
This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF
Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction
This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.
SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations
A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (
Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker
An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai
PAD4, NETs, and Inflammasome Activation: A New Mechanistic Link Between Diabetes and Cardiorenal Injury
A translational study links hyperglycaemia-driven PAD4-dependent neutrophil extracellular trap (NET) formation and inflammasome activation to cardiac and renal inflammation, fibrosis, and heart failure in experimental diabetes—suggesting no
Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety
The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.
Biomarker-Guided Preventive Care Halves Risk of Moderate–Severe AKI After Major Surgery: Results from BigpAK-2
In BigpAK-2, a multinational randomized trial, a KDIGO-based preventive bundle triggered by tubular stress biomarkers reduced moderate or severe acute kidney injury within 72 hours after major surgery (OR 0.57; NNT 12) without increasing ad
Browse by specialty
Open language-specific specialty feeds and department pages.